NewcelX logo
NewcelX
NCEL | NASDAQ
Chart Builder DCF Calculator
$2.75
+$0.14 (+5.36%)
At close: Nov 16, 2026, 4:00 PM ET
$2.75
$0.00 (0.00%)
After-hours: Nov 16, 2026, 7:30 PM ET

NewcelX Company Profile

Company profile explained

Company Profile

NewcelX Ltd., a biotechnology firm established in 2008 and based in Zurich, Switzerland, is dedicated to advancing groundbreaking therapeutic solutions. The company's focus lies in developing innovative treatments, utilizing both cell-based and small-molecule approaches, to address challenging neurodegenerative and metabolic diseases.

Key Executives

Name Position
Ronen Twito Chief Executive Officer & Executive Chairman
Omri Hagai Chief Financial Officer
Alexander Zwyer Chief Business Officer & Executive Director
Ariel Revel Director of Medical Affairs
Eric Konofal Head of Doxa Program
Michel Revel Co-Founder, Chief Scientist, Head of the Scientific Advisory Board & Director

Latest SEC Filings

Date Type Title
Sep 22, 2026 EFFECT Filing
Sep 18, 2026 POS AM Filing
Sep 18, 2026 6-K Filing
Aug 26, 2026 EFFECT Filing
Aug 24, 2026 D Filing
Aug 20, 2026 F-3 Filing
Aug 03, 2026 6-K Filing
Jul 31, 2026 6-K Filing
Jul 15, 2026 6-K Filing
Jul 08, 2026 6-K Filing
View All SEC Filings ➞
NewcelX
NewcelX logo
Country Switzerland
IPO Date Oct 24, 2025
Industry Biotechnology
Sector Healthcare
Employees 11
CEO Ronen Twito

Contact Details

Hohstrasse 1 Kloten, ZH 8302 Switzerland

Stock Details

Ticker Symbol NCEL
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001783036
CUSIP Number H5835A109
ISIN Number CH1442297896
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.